相关实验视频

Updated: Jul 29, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

贝佩多酸:一种新兴的治疗方法,用于控制不良的低密度脂蛋白 (LDL) 胆固醇

Akshyaya Pradhan¹, Monika Bhandari¹, Pravesh Vishwakarma¹

¹Department of Cardiology, King George's Medical University, Lucknow 226003, India.

Journal of cardiovascular development and disease

|May 26, 2023

概括

班佩多酸有效降低LDL胆固醇,为动脉样硬化心血管疾病 (ASCVD) 患者提供了一个新的选择,这些患者仅使用他类药物就无法达到目标. 这种新型药物对心血管有好处,肌肉副作用比他类药物少.

科学领域:

心脏病学和脂质学.
新型降脂剂的药理学新型降脂剂的药理学

背景情况:

动脉样硬化心血管疾病 (ASCVD) 构成了全球健康负担,特别是在印度等发展中国家,由于高血脂不良的流行率.
低密度脂蛋白胆固醇 (LDL-C) 是ASCVD的主要驱动因素;他类药物是第一线治疗,但面临肌肉症状,血糖问题和治疗目标实现等挑战.
像PCSK-9抑制剂和inclisiran这样的新兴疗法是有效的,但受管理途径和成本的限制,创造了替代降脂策略的需求.

研究的目的:

为了评估bempedoic酸,一种新型ATP酸酶 (ACL) 抑制剂,作为一种降脂剂,用于患有脱脂症和ASCVD的患者.
评估bempedoic酸降低LDL-C的疗效,无论是单一治疗还是与其他药物结合使用,以及其对心血管结果的影响.
与安慰剂和现有疗法相比,研究bempedoic酸的安全性,特别是与肌肉相关的症状和血糖控制有关的安全性.

主要方法:

分析了来自CLEAR试验的数据,这是一系列四项随机对照试验,涉及4000多名ASCVD患者.
评估bempedoic酸降低LDL-C的疗效,在史坦丁先前未使用的患者和那些在现有史坦丁治疗.
评估CLEAR Outcomes试验,这是一项评估40个月内主要心血管不良事件 (MACE) 的心血管结局试验.

主要成果:

班佩多酸通过抑制他类药物的ACL上游,显著降低了LDL-C (22-28%在史塔丁先者中,17-18%在史塔丁患者中).
与ezetimibe的联合治疗导致协同降低LDL-C (39%),没有对血糖指标的不良影响,并且降低了hsCRP.
清晰的结局试验显示,MACE在40个月内减少了13%;增加尿酸和痛风发病率被认为是潜在的副作用.

结论:

佩多酸为治疗失脂症和降低ASCVD风险提供了一种有价值的新疗法选择,特别是对于那些无法通过他类药物达到LDL-C目标的患者.
它独特的作用机制,最小的与肌肉相关的副作用,以及证明的心血管益处使其成为降脂武器的重要补充.
虽然一般耐受性很好,但建议对尿酸和痛风的潜在增加进行监测.

关键词:

在ATP酸盐溶解酶.贝佩多酸是贝佩多酸的一种酸.这就是为什么LDL胆固醇是LDL胆固醇.类他类药物不耐受性尿酸是什么尿酸是什么尿酸是什么

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...